Arq, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Arq, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $25.76M | Mar 8, 2022 |
| FY2021 | Sep 30, 2021 | $30.86M | Mar 8, 2022 |
| FY2021 | Jun 30, 2021 | $21.07M | Mar 8, 2022 |
| FY2021 | Mar 31, 2021 | $22.61M | Mar 8, 2022 |
| FY2021 | Dec 31, 2020 | $19.74M | Mar 8, 2022 |
| FY2021 | Sep 30, 2020 | $21.27M | Mar 8, 2022 |
| FY2021 | Jun 30, 2020 | $12.73M | Mar 8, 2022 |
| FY2021 | Mar 31, 2020 | $13.62M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | $16.05M | Mar 10, 2021 |
| FY2020 | Sep 30, 2019 | $19.13M | Mar 10, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($52.61M) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | ($5.11M) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | ($12.25M) | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | ($8.92M) | Mar 12, 2024 |
| FY2021 | Dec 31, 2021 | $5.82M | Mar 8, 2022 |
| FY2021 | Sep 30, 2021 | $24.25M | Mar 8, 2022 |
| FY2021 | Jun 30, 2021 | $16.59M | Mar 8, 2022 |
| FY2021 | Mar 31, 2021 | $13.74M | Mar 8, 2022 |
| FY2021 | Dec 31, 2020 | $430.0K | Mar 8, 2022 |
| FY2021 | Sep 30, 2020 | $4.98M | Mar 8, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($52.96M) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | ($1.96M) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | ($13.34M) | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | ($12.07M) | Mar 12, 2024 |
| FY2021 | Dec 31, 2021 | $784.0K | Mar 8, 2022 |
| FY2021 | Sep 30, 2021 | $3.30M | Mar 8, 2022 |
| FY2021 | Jun 30, 2021 | $439.0K | Mar 8, 2022 |
| FY2021 | Mar 31, 2021 | $330.0K | Mar 8, 2022 |
| FY2021 | Dec 31, 2020 | $1.55M | Mar 8, 2022 |
| FY2021 | Sep 30, 2020 | ($2.83M) | Mar 8, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.34M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $4.05M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $3.31M | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | $2.10M | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | $400.0K | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $1.00M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | $200.0K | Mar 10, 2021 |
| FY2017 | Dec 31, 2017 | $157.0K | Mar 12, 2018 |
| FY2017 | Dec 31, 2016 | ($648.0K) | Mar 12, 2018 |
| FY2017 | Dec 31, 2015 | $5.36M | Mar 12, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $22.55M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $28.70M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $34.07M | Mar 5, 2025 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.73M) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $10.48M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | ($16.65M) | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | ($6.06M) | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | $26.00M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $54.05M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | $62.26M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | ($9.89M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | ($11.75M) | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | ($18.26M) | Mar 12, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $485.0K | Mar 12, 2018 |
| FY2017 | Dec 31, 2016 | $289.0K | Mar 12, 2018 |
| FY2017 | Dec 31, 2015 | $507.0K | Mar 12, 2018 |
| FY2016 | Dec 31, 2014 | $1.56M | Mar 13, 2017 |
| FY2015 | Dec 31, 2013 | $2.14M | Apr 19, 2016 |
| FY2014 | Dec 31, 2012 | $3.88M | Mar 17, 2016 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $230.58M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $284.37M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $235.50M | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | $181.16M | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | $185.44M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $146.67M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | $173.80M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $159.66M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $82.62M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $107.30M | Mar 12, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $62.62M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $67.09M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $57.10M | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | $41.19M | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | $38.14M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $61.46M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | $65.51M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $91.72M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $9.16M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $31.13M | Mar 12, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $167.96M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $217.28M | Mar 10, 2026 |
| FY2025 | Dec 31, 2023 | $178.40M | Mar 10, 2026 |
| FY2024 | Dec 31, 2022 | $139.98M | Mar 5, 2025 |
| FY2023 | Dec 31, 2021 | $147.30M | Mar 12, 2024 |
| FY2021 | Dec 31, 2020 | $85.21M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | $108.29M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $67.95M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $73.46M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $76.17M | Mar 12, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.82M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $66.43M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $71.54M | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | $83.95M | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | $92.86M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $32.45M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | $57.34M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $12.91M | Mar 16, 2020 |
| FY2018 | Jan 1, 2018 | ($12.53M) | Mar 18, 2019 |
| FY2018 | Dec 31, 2017 | ($15.48M) | Mar 18, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.57M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $13.52M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $45.36M | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | $66.43M | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | $78.75M | Mar 8, 2023 |
| FY2017 | Dec 31, 2017 | $30.69M | Mar 12, 2018 |
| FY2017 | Dec 31, 2016 | $13.21M | Mar 12, 2018 |
| FY2016 | Dec 31, 2015 | $9.27M | Mar 13, 2017 |
| FY2015 | Dec 31, 2014 | $25.18M | Apr 19, 2016 |
| FY2015 | Dec 31, 2013 | $37.89M | Apr 19, 2016 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $28.70M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $25.08M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $22.99M | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | $4.58M | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | $3.15M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $5.45M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | $20.43M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $50.06M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $0 | Mar 18, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 12, 2024 |
| FY2021 | Dec 31, 2021 | 0 | Mar 8, 2022 |
| FY2021 | Sep 30, 2021 | 1 | Mar 8, 2022 |
| FY2021 | Jun 30, 2021 | 0 | Mar 8, 2022 |
| FY2021 | Mar 31, 2021 | 0 | Mar 8, 2022 |
| FY2021 | Dec 31, 2020 | 0 | Mar 8, 2022 |
| FY2021 | Sep 30, 2020 | 0 | Mar 8, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 12, 2024 |
| FY2021 | Dec 31, 2021 | 0 | Mar 8, 2022 |
| FY2021 | Sep 30, 2021 | 1 | Mar 8, 2022 |
| FY2021 | Jun 30, 2021 | 0 | Mar 8, 2022 |
| FY2021 | Mar 31, 2021 | 0 | Mar 8, 2022 |
| FY2021 | Dec 31, 2020 | 0 | Mar 8, 2022 |
| FY2021 | Sep 30, 2020 | 0 | Mar 8, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 42.73M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | 42.02M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | 33.17M | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | 19.17M | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | 18.84M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | 18.52M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | 18.36M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | 18.58M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | 20.75M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | 22.02M | Mar 12, 2018 |